SG11201901501UA - Compositions and methods for enhancing cancer radiotherapy - Google Patents

Compositions and methods for enhancing cancer radiotherapy

Info

Publication number
SG11201901501UA
SG11201901501UA SG11201901501UA SG11201901501UA SG11201901501UA SG 11201901501U A SG11201901501U A SG 11201901501UA SG 11201901501U A SG11201901501U A SG 11201901501UA SG 11201901501U A SG11201901501U A SG 11201901501UA SG 11201901501U A SG11201901501U A SG 11201901501UA
Authority
SG
Singapore
Prior art keywords
international
pct
radiotherapy
compositions
irvine
Prior art date
Application number
SG11201901501UA
Inventor
Houn Simon Hsia
Original Assignee
Houn Simon Hsia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Houn Simon Hsia filed Critical Houn Simon Hsia
Publication of SG11201901501UA publication Critical patent/SG11201901501UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pediatric Medicine (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Jellies, Jams, And Syrups (AREA)

Abstract

FIGD TR ratrAWM • \"-\" ••••••••• ••••••••• PTRN (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 12 April 2018 (12.04.2018) WIPO I PCT °Ens OH oI0III11010101111010IIIIIIIII111111 0IIIIII (10) International Publication Number WO 2018/067604 Al (51) International Patent Classification: A23L 33/00 (2016.01) A61N 5/10 (2006.01) (21) International Application Number: PCT/US2017/054988 (22) International Filing Date: 03 October 2017 (03.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/403,630 03 October 2016 (03.10.2016) US (72) Inventor; and (71) Applicant: HSIA, Houn Simon [US/US]; 17201 Daimler Street, Irvine, California 92614 (US). (74) Agent: BRILLHART, Kurt L. et al.; Fish IP Law, LLC, 2603 Main Street, Ste 1000, Irvine, California 92614 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: COMPOSITIONS AND METHODS FOR ENHANCING CANCER RADIOTHERAPY (57) : A nutritional supplement is described that enhances and provides synergistic effects when used in combination with radiotherapy to treat tumors, both reducing tumor size and preventing metastasis. The nutritional supplement has been also found to be effective in reducing negative side effects of concurrent radiotherapy, including inflammation, weight loss, muscle wasting, neutropenia, and loss of cells from the lining of the gut.
SG11201901501UA 2016-10-03 2017-10-03 Compositions and methods for enhancing cancer radiotherapy SG11201901501UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662403630P 2016-10-03 2016-10-03
PCT/US2017/054988 WO2018067604A1 (en) 2016-10-03 2017-10-03 Compositions and methods for enhancing cancer radiotherapy

Publications (1)

Publication Number Publication Date
SG11201901501UA true SG11201901501UA (en) 2019-04-29

Family

ID=61831274

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901501UA SG11201901501UA (en) 2016-10-03 2017-10-03 Compositions and methods for enhancing cancer radiotherapy

Country Status (9)

Country Link
US (2) US11206861B2 (en)
EP (1) EP3518689A4 (en)
JP (2) JP7123945B2 (en)
KR (1) KR102402485B1 (en)
CN (1) CN110312439A (en)
CA (2) CA3038327C (en)
IL (1) IL265786B (en)
SG (1) SG11201901501UA (en)
WO (1) WO2018067604A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3638270B1 (en) 2017-06-13 2023-10-25 Houn Simon Hsia Compositions and methods for enhancing hyperthermia therapy
KR20200078467A (en) * 2017-06-13 2020-07-01 호운 사이먼 샤 Compositions and methods for improving cancer radiotherapy
CN110236977B (en) * 2019-06-06 2022-08-02 好维股份有限公司 An oral care composition comprising stabilized EGCg
EP4051261A4 (en) * 2019-10-28 2023-08-02 Cora Therapeutics Inc. Formulation to reduce or prevent oxidative stress damage
EP4132298A1 (en) * 2020-04-09 2023-02-15 Prabhakaran PANDURANGAN A therapeutic composition
US11147835B1 (en) 2020-08-20 2021-10-19 Frank Kelly Reilly, III Nutritional supplement
CN112870224B (en) * 2021-01-15 2022-04-22 南京大学 Radiotherapy sensitizer and preparation method thereof
CN113667602B (en) * 2021-08-03 2024-05-28 广东省人民医院 High-purity stem cell culture automation equipment
CN115770255A (en) * 2021-09-07 2023-03-10 深圳奥萨医药有限公司 Composition for adjuvant treatment of cancerous fever
CN116144724B (en) * 2023-04-23 2023-07-18 养系列(山东)生物科技有限公司 Composite peptide and spray for rehabilitation of tumor patients and preparation method thereof
CN117398339B (en) * 2023-12-13 2024-04-02 养系列(山东)生物科技有限公司 Sustained-release polypeptide for tumor patients after chemotherapy and preparation method and application thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348483A (en) 1981-01-23 1982-09-07 Universal Foods Corporation Method for the production of chromium yeast
US4569836A (en) 1981-08-27 1986-02-11 Gordon Robert T Cancer treatment by intracellular hyperthermia
CA2010511A1 (en) 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
US20020010144A1 (en) 1994-04-29 2002-01-24 Robert Sobol Enhancing the sensitivity of tumor cells to therapies
US5976548A (en) 1994-11-08 1999-11-02 Viva America Marketing, Inc. Nutritional supplement composition and use
US6440464B1 (en) 1996-06-10 2002-08-27 Viva Life Science Nutritive composition for cardiovascular health containing fish oil, garlic, rutin, capsaicin, selenium, vitamins and juice concentrates
US6197295B1 (en) 1996-09-25 2001-03-06 Viva America Marketing Corporation Dietary supplementation with, and methods for administration of yeast-derived selenium product
US5810888A (en) 1997-06-26 1998-09-22 Massachusetts Institute Of Technology Thermodynamic adaptive phased array system for activating thermosensitive liposomes in targeted drug delivery
CA2339473A1 (en) 1998-08-04 2000-02-17 John V. Kosbab Nutrient and therapeutic compositions for the treatment of cancer
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
JP2004533870A (en) 2001-03-26 2004-11-11 エレン・エイ・インコーポレーテッド Method and apparatus for treating diseased tissue
US20050013875A1 (en) 2001-10-25 2005-01-20 Takeshi Kobayashi Immunopotentiators in thermotherapy for cancer
CA2471932A1 (en) * 2002-01-11 2003-07-17 Matthias Rath A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
US20040087490A1 (en) 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
AU2002951833A0 (en) 2002-10-02 2002-10-24 Novogen Research Pty Ltd Compositions and therapeutic methods invloving platinum complexes
US7744930B2 (en) 2002-11-22 2010-06-29 Shaklee Corporation Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
US20060088574A1 (en) * 2004-10-25 2006-04-27 Manning Paul B Nutritional supplements
US8017147B2 (en) 2008-04-07 2011-09-13 Mazed Mohammad A Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance
NZ555163A (en) * 2007-05-14 2010-05-28 Fonterra Co Operative Group Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments
US20090110674A1 (en) 2007-10-24 2009-04-30 Loizou Nicos C Health supplement
WO2009157759A1 (en) 2008-06-23 2009-12-30 N.V. Nutricia Nutritional composition for improving the mammalian immune system
AU2009293475A1 (en) * 2008-09-19 2010-03-25 Nestec S.A. Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment
US8257694B2 (en) 2009-05-14 2012-09-04 Product Partners, Llc Nutritional compositions for reducing oxidative damage
CN101569410A (en) * 2009-05-22 2009-11-04 刘志伟 Special meal nutritional foods used by tumor patients
CA3018176C (en) 2009-05-29 2020-06-23 Board Of Regents Of The University Of Texas System Compositions and methods for modulating lipid composition
KR101275724B1 (en) 2009-12-09 2013-06-17 한국전자통신연구원 Monolithic microwave integrated circuit device and method for forming the same
WO2011094579A2 (en) 2010-01-29 2011-08-04 New Chapter Inc. Mushroom compositions and methods for making and using
JP5882889B2 (en) 2010-03-15 2016-03-09 国立大学法人 岡山大学 Antitumor agent
WO2011146635A1 (en) * 2010-05-21 2011-11-24 North Texas Medical Associates Malignant neoplasm treatment protocol
US20120010688A1 (en) 2010-07-09 2012-01-12 Lamb Karl J Implantable conductive element and method of use inhyperthermic treatment
WO2012122295A2 (en) * 2011-03-07 2012-09-13 Ned Biosystems, Inc. Treatment for pancreatic adenocarcinoma and other cancers of epithelial origin
WO2014054884A1 (en) 2012-10-05 2014-04-10 연세대학교 산학협력단 Composition for hyperthermia comprising sensitization material
US9072768B2 (en) * 2013-01-22 2015-07-07 Kibow Biotech, Inc. Composition and method for increasing effectiveness of radiation or chemotherapy
US9107947B2 (en) 2013-01-31 2015-08-18 The Penn State Research Foundation Anti-cancer compositions and methods
US9889092B2 (en) 2013-03-13 2018-02-13 The Board Of Regents Of The University Of Texas System Low density lipoprotein nanocarriers for targeted delivery of omega-3 polyunsaturated fatty acids to cancer
US20140294795A1 (en) * 2013-03-28 2014-10-02 Houn Simon Hsia Nutritional Composition
PL2991507T3 (en) 2013-04-22 2020-02-28 Smartfish As Use of a composition comprising fish oil and juice for the treatment and/or post treatment of cancer
JP2016531114A (en) 2013-07-31 2016-10-06 株式会社明治 Nutritional composition that inhibits tumor growth
CN105658226B (en) 2013-08-16 2019-05-14 港大科桥有限公司 Use the method and composition of probiotics agents treatment cancer
US20170246136A1 (en) 2014-09-24 2017-08-31 OliVentures, Inc. Pharmaceutical product, medical food or dietary supplement for preventing cancer and inflammatory diseases
CN105641000A (en) 2015-06-01 2016-06-08 深圳市康道生物有限公司 Antitumor composition containing grifola frondosus extract and preparation method thereof
CN105768108A (en) * 2016-03-10 2016-07-20 福格森（武汉）生物科技股份有限公司 Special dietary food suitable for taking of tumor patients
JP6376186B2 (en) 2016-08-04 2018-08-22 トヨタ自動車株式会社 Suspension member
KR20200078467A (en) * 2017-06-13 2020-07-01 호운 사이먼 샤 Compositions and methods for improving cancer radiotherapy
US10905725B2 (en) * 2017-06-13 2021-02-02 Houn Simon Hsia Compositions and methods for enhancing cancer chemotherapy
EP3638270B1 (en) * 2017-06-13 2023-10-25 Houn Simon Hsia Compositions and methods for enhancing hyperthermia therapy

Also Published As

Publication number Publication date
US20220095667A1 (en) 2022-03-31
CN110312439A (en) 2019-10-08
KR102402485B1 (en) 2022-05-25
KR20190067828A (en) 2019-06-17
CA3038327C (en) 2024-03-12
US11206861B2 (en) 2021-12-28
IL265786A (en) 2019-06-30
JP2022160655A (en) 2022-10-19
US20200260772A1 (en) 2020-08-20
JP2019529578A (en) 2019-10-17
CA3228010A1 (en) 2018-04-12
WO2018067604A1 (en) 2018-04-12
EP3518689A1 (en) 2019-08-07
JP7465313B2 (en) 2024-04-10
IL265786B (en) 2022-09-01
EP3518689A4 (en) 2019-10-30
JP7123945B2 (en) 2022-08-23
CA3038327A1 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
SG11201901501UA (en) Compositions and methods for enhancing cancer radiotherapy
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201908532UA (en) Macrocyclic compounds as ros1 kinase inhibitors
SG11201901126UA (en) Combination therapy for cancer
SG11201810423XA (en) Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201907650RA (en) Personal therapy and exercise monitoring and oversight devices, systems, and related methods
SG11201808125RA (en) Methods for solid tumor treatment
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201809751XA (en) Egfr inhibitor compounds
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201907023UA (en) Method of reducing neutropenia
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201806342SA (en) Glucagon and glp-1 co-agonists for the treatment of obesity
SG11201805001UA (en) Method of treating influenza a
SG11201909837YA (en) Methods for treating lung disorders
SG11201900361RA (en) Methods of treating prostate cancer
SG11201805385QA (en) Bromodomain and extra-terminal protein inhibitor combination therapy
SG11201900486WA (en) Treatment and prevention of sleep disorders
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201804587QA (en) Isoindole compounds
SG11201809875VA (en) Compositions and methods for treating spinal muscular atrophy
SG11201807915QA (en) Differentiation of pluripotent stem cells to intestinal midgut endoderm cells
SG11201903427UA (en) Deodorizing agent comprising zinc neodecanoate
SG11201811482YA (en) Double targeted constructs to affect tumor kill